73 results about "Myofibrosis" patented technology

The method for determining the myocardial fibrosis evaluation model comprises the following steps: acquiring an ultrasonic image of a target rabbit in an echocardiography; performing feature extraction on the ultrasonic image by using a plurality of preset feature extraction models to form a plurality of feature sets; performing representative feature screening on each feature set by using a plurality of preset feature screening models to form a plurality of feature representative sets; performing feature classification on each feature representative set by using various preset classifiers to form a plurality of classification results; and determining a myocardial fibrosis evaluation model according to the classification result corresponding to each feature set. The problem that in the prior art, no auxiliary diagnosis technology for myocardial fibrosis of living organisms through ultrasonic image analysis exists is solved, robust evaluation on the severity of myocardial fibrosis of people is promoted, and early detection and longitudinal monitoring become possible.

The invention relates to the field of biomedicine, in particular to application of PXDC1 in preparation of a product for treating myocardial hypertrophy. The invention discloses the effectiveness of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and development process of the cardiac hypertrophy for the first time. The invention provides a novel drug target and strategy for treating myocardial hypertrophy, and the novel drug target and strategy can reduce the expression of a myocardial hypertrophy biomarker, reduce the size of myocardial cells, improve the ejection fraction and short axis shortening rate of the heart, reduce the weight ratio of the heart and relieve the degree of myocardial fibrosis. Besides, the invention clarifies the action mechanism of PXDC1 in myocardial hypertrophy, deepens the understanding of the pathogenesis of the disease, and lays an important foundation for further exploration of myocardial hypertrophy-related cytobiology and molecular biology processes.

The invention provides a polypeptide. The amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. Specifically, the sequence of the polypeptide is as follows: MTSRQEDASGKKTTEGAKFQGS. The invention also provides a DNA (deoxyribonucleic acid) molecule for coding the polypeptide according to the claim 1. The invention also provides a recombinant vector containing the DNA molecule. The invention also provides application of the polypeptide in preparation of medicines for treating myocardial fibrosis. The invention further provides a pharmaceutical composition, and the effective component of the pharmaceutical composition is the polypeptide. Experiments prove that the traditional Chinese medicine can relieve myocardial fibrosis.

The invention relates to the technical field of medicines, in particular to application of OpiCa1 or a nano-liposome thereof in preparation of medicines for treating and / or preventing myocardial fibrosis related diseases. The research on modeling and administration of myocardial infarction mice finds that the OpiCa1 and the nano-liposome thereof can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and have a better antagonistic effect on myocardial infarction and subsequent heart failure. Further transcriptomics analysis shows that in the process of treating the myocardial infarction of mice, the OpiCa1 and the nano-liposome thereof may participate in extracellular matrix degradation in myocardial remodeling and fibrosis pathways (such as TGF-beta signal pathways) to inhibit fibrosis and improve myocardial remodeling, and the purpose of relieving deterioration of the myocardial infarction is achieved.

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

The invention provides an SLC25A4 gene as well as an interferent and application thereof, and relates to the technical field of biomedicine. The SLC25A4 gene interferent is injected into a mouse body and is continuously released, so that the processes of mitochondrial injury and pyroptosis are inhibited, and the myocardial fibrosis and cardiac remodeling after myocardial infarction are reduced.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to define the effect of connexin43 in the cardiac hypertrophy process caused by myocardial cell hypertrophy induced by pathological matrix stiffness and pressure overload, the invention provides application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the application disclosed by the invention, the Connexin43 gene is found to be used as a potential target for preventing or treating myocardial fibrosis for the first time, and a myocardial cell hypertrophy process induced by pathological matrix hardness and a myocardial hypertrophy process caused by overload of pressure can be relieved by knocking down the expression of the Connexin43 gene or inhibiting the semi-channel activity of the Connexin43. Therefore, the inhibitor targeting the Connexin43 gene can be used for preparing the medicine for preventing or treating the myocardial fibrosis, and a new way is provided for treating the myocardial fibrosis.

The invention belongs to the technical field of biological medicines, and particularly provides a small molecule compound E229-0305 for preparing a medicine for treating myocardial fibrosis. The small molecule compound E229-0305 can target PTGS2 protein, inhibit fibrosis of myocardial fibroblasts induced by TGF-beta1, reduce proliferation and migration capabilities of the myocardial fibroblasts, inhibit the fibroblasts from being converted into myofibroblasts, and inhibit expression of fibrosis-related genes and proteins. Besides, in a model of myocardial fibrosis after myocardial infarction of a mouse, the small molecule compound E229-0305 improves the cardiac function of the mouse with myocardial infarction and reduces the fibrosis area and collagen deposition of the heart. The small molecule compound E229-0305 can be used as a brand-new targeted PTGS2 small molecule inhibitor for preparing medicines for preventing and treating myocardial fibrosis.

The invention discloses a traditional Chinese medicine composition for treating acute myocardial infarction, a pharmaceutical preparation and application thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-18 parts of ginseng, 3-6 parts of pseudo-ginseng, 9-18 parts of ligusticum wallichii, 12-24 parts of radix achyranthis bidentatae, 6-12 parts of fructus forsythiae and 9-18 parts of radix curcumae. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention has the beneficial effects that (1) the traditional Chinese medicine composition provided by the invention can reduce the myocardial infarction area after ischemia, inhibit myocardial fibrosis and improve heart structure and function changes caused by acute ischemic injury; and (2) the traditional Chinese medicine composition provided by the invention can effectively inhibit oxidative stress reaction and relieve mitochondrial injury, thereby playing a role in protecting the heart. And (3) the traditional Chinese medicine composition has the advantage of good safety and can be taken for a long time.

This invention provides a polypeptide whose amino acid sequence is shown in SEQ ID NO.1. Specifically, the sequence of the polypeptide is: MTSRQEDASGKKTTEGAKFQGS. This invention also provides a DNA molecule encoding the polypeptide of claim 1. This invention further provides a recombinant vector containing the above-mentioned DNA molecule. This invention also provides the use of the above-mentioned polypeptide in the preparation of a medicament for treating myocardial fibrosis. This invention also provides a pharmaceutical composition in which the above-mentioned polypeptide is the active ingredient. Experiments have shown that this invention can alleviate myocardial fibrosis.

To provide a method of treating cardiac fibrosis in a patient.SOLUTION: The present invention relates to a method of treating cardiac fibrosis in a patient, comprising administering to the patient a therapeutically effective amount of an αV-integrin inhibitor. Pharmacological blockade of αV-containing integrins improved cardiac function and survival after MI by reducing infarct size and attenuating expansion of reactive cardiac fibrosis. Notably, after pharmacological blockade of αV-containing integrins, a total myocardial fibrogenesis area as well as interstitial fibrosis in the remote myocardial area are significantly reduced. These data identify a novel mechanism regulating cardiac fibrosis in response to an ischemic injury and suggest that pharmacological targeting of αV-integrins may provide clinical benefit in the treatment of cardiac fibrosis.SELECTED DRAWING: None

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-propionic acid in preparation of a medicine for treating myocardial ischemia-reperfusion injury. A stable and reliable mouse MIRI model is successfully constructed through a coronary artery ligation left anterior descending branch reperfusion method, and it is found through indole-3-propionic acid (IPA) intervention and multi-dimensional evaluation that IPA administration can significantly improve the left ventricular ejection fraction LVEF and the left ventricular short-axis shortening rate LVFS of a model mouse, reduce the left ventricular end diastolic inner diameter LVEDd and the end systolic inner diameter LVESd, and significantly improve the model mouse left ventricular ejection fraction LVEF, the left ventricular end diastolic inner diameter LVEDd and the left ventricular end diastolic inner diameter LVESd. The heart function is effectively improved; the myocardial fibrosis area can be reduced, the mRNA expression of fibrosis-promoting and pathological hypertrophy-promoting molecules in myocardial tissues can be obviously reduced, and the myocardial injury progress can be inhibited in a multi-dimensional manner. The invention provides a brand new strategy for treating myocardial ischemia reperfusion injury, has important application value and wide clinical transformation prospect, and is expected to provide a new direction for clinical treatment.

The invention discloses a diagnosis marker for diabetes complicated with atrial fibrillation and application of the diagnosis marker, and relates to the technical field of biological medicine. The diagnostic marker is hematopoietic cell kinase (HCK). The invention finds that HCK can effectively predict the occurrence risk of diabetes mellitus combined with atrial fibrillation and provide an effective treatment target for diabetes mellitus combined with atrial fibrillation. The invention verifies that the knock-down HCK can effectively inhibit AGEs-induced HL-1 cell CaMKII phosphorylation, myocardial fibrosis, mitochondrial membrane potential damage and ROS generation, and alleviates the inhibition effect on AMPK / mTOR signal channel activation, thereby reducing the atrial fibrillation susceptibility. The invention also proves that the risk (AUC is 0.853) of the diabetic with atrial fibrillation can be accurately identified by detecting the HCK level in the plasma. The invention provides a new medical approach for early risk assessment and targeted intervention of diabetes mellitus combined with atrial fibrillation.

The invention discloses an application of a disulfiram medicine in improving sepsis induced cardiomyopathy. The disulfiram drug is administered in a sepsis mouse model, and the disulfiram drug is proved to have obvious anti-inflammatory effect and myocardial protection effect. The disulfiram medicine can relieve myocardial hypertrophy of mice, relieve the degree of myocardial fibrosis and reduce myocardial interstitial inflammatory exudation, ZO-1 reconstructs continuous linear distribution after administration, and the degree of myocardial edema is obviously relieved. The invention provides a new application of the disulfiram medicine in improving sepsis-induced cardiomyopathy, and provides a new strategy for myocardial protection of sepsis.

The invention discloses a traditional Chinese medicine composition for treating heart failure, and particularly relates to the field of traditional Chinese medicine compositions. Comprising the following raw materials in parts by weight: 160 parts of red ginseng, 160 parts of dogwood and 80 parts of salvia miltiorrhiza. The traditional Chinese medicine composition in the scheme achieves the purpose of treating heart failure by regulating and controlling a Hippo-YAP pathway. By adopting the technical scheme, a new method is provided for treating the heart failure at present, and the traditional Chinese medicine composition has the advantage of low cost, is beneficial to reducing the myocardial fibrosis degree of a heart failure mouse in an experiment, and is beneficial to improving the cardiac function of a patient and improving the life quality in a clinical test.

The present application relates to the technical field of biological medicine, in particular to application of aconitum brachypodum franch alcohol extract in myocardial protection, and discloses that the aconitum brachypodum franch alcohol extract mainly inhibits formation of myocardial fibrosis, reduces inflammatory reaction and reduces cell apoptosis by adjusting a TLR4 / MyD88 / NF-kappa B channel, thereby protecting ISO-induced myocardial injury of a mouse; the present application provides a theoretical basis for improving myocardial injury by the aconitum brachypodum franch, and also provides a scientific basis for development and utilization of the aconitum brachypodum franch.

The invention belongs to the technical field of biological medicines, and relates to application of histone demethylase KDM4A as a target spot, in particular to application of the histone demethylase KDM4A as the target spot in preparation of medicines for treating myocardial fibrosis and heart failure. The KDM4A is determined to be capable of mediating myocardial fibroblast aging so as to promote fibrosis of myocardial tissues and lead to heart failure. The invention provides a method for screening the medicine for treating myocardial fibrosis and heart failure by taking KDM4A as a target spot for the first time, and provides the medicine for treating myocardial fibrosis and heart failure, namely the medicine for regulating and controlling cardiac muscle fiber cell senescence to inhibit myocardial fibrosis.

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

The invention belongs to the field of biological medicine, and particularly relates to a traditional Chinese medicine composition for treating heart yin deficiency and myocardial fibrosis and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: 5-13 parts of lily, 5-13 parts of radix ophiopogonis, 3-9 parts of ginseng, 5-13 parts of radix scrophulariae, 3-9 parts of semen boitae and 1-5 parts of schisandra chinensis. The invention also provides a preparation method of the composition. The composition has the effects of reinforcing qi, nourishing yin, calming the heart and tranquilizing the mind, and can be used for preparing medicines for treating heart-yin deficiency and myocardial fibrosis or improving heart-yin deficiency symptoms. Experimental results show that the traditional Chinese medicine composition can significantly improve the heart function of a chronic heart failure model mouse, inhibit myocardial cell hypertrophy and collagen deposition, and down-regulate fibrosis-related gene expression. Clinical observation shows that the traditional Chinese medicine can effectively relieve the symptoms of palpitation, insomnia, dysphoria with smothery sensation and the like of patients with heart yin deficiency. The traditional Chinese medicine composition is clear in formula and controllable in quality, and a novel safe and effective traditional Chinese medicine choice is provided for treating heart yin deficiency related myocardial fibrosis.

The application discloses application of a composition containing tanshinone extract and muscone, and belongs to the technical field of medicines. The compatibility and ratio control of the tanshinone extract and the muscone can inhibit expression and / or secretion of FSTL1 of cardiac fibroblasts at a molecular level, regulate related fibrosis signal pathways, thereby inhibiting a myocardial fibrosis process, and producing a synergistic effect with anti-myocardial injury, improving ventricular structure and function abnormalities after myocardial infarction, and being used for treating cardiovascular diseases such as myocardial infarction, myocardial fibrosis and heart failure after myocardial infarction. The composition of the application comprises the tanshinone extract and the muscone, and can be used for preparing a medicine for preventing and treating cardiovascular diseases with better effects.

The application belongs to the technical field of biological medicine, and particularly relates to a use of Serpine1 gene as a target in preparation of a drug for preventing or treating myocardial fibrosis. In order to screen key molecules for intervention and regulation of extracellular matrix balance, and provide a basis for development of a drug for preventing or treating myocardial fibrosis, the application determines important functions of Serpine1 in myocardial fibrosis through experiments, and provides a use of Serpine1 gene as a target in preparation of a drug for preventing or treating myocardial fibrosis. The application verifies through experiments that knocking down expression of Serpine1 can improve impaired cardiac systolic function caused by thoracic aortic arch constriction for 4 weeks, reduce myocardial fibrosis, and inhibit activation of myocardial fibroblasts, and can be used for preparation of a drug for preventing or treating myocardial fibrosis, and has important practical significance.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving heart failure and its preparation method. The traditional Chinese medicine composition for improving heart failure comprises the following raw materials in parts by weight: astragaloside A 4-7 parts, arctiin 8-12 parts, citrinin 3-6 parts, and perilla lactone 2-4 parts. Experimental results show that taking the traditional Chinese medicine composition for improving heart failure prepared according to this invention has the effects of tonifying heart qi, warming yang and tonifying kidney, promoting blood circulation and detoxifying, and reducing swelling and promoting diuresis, thereby effectively improving cardiac function, inhibiting excessive activation of the RAAS system, reducing myocardial damage and myocardial fibrosis, and significantly alleviating heart failure symptoms. Furthermore, the traditional Chinese medicine composition provided by this invention has precise formulation, few toxic side effects, high safety, and broad application prospects.

The present disclosure discloses use of a polypeptide, relating to the field of biopharmaceuticals. The polypeptide comprises the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Arg-Gly-Ala-Asp-Arg-Ala; or a sequence of any amino acid mutated in the foregoing domains. The polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, myelofibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, and lung tissue lesions.

The present invention belongs to the field of biomedicine technology, and specifically relates to a circSamd4 and its use in the preparation of a drug for treating myocardial fibrosis. In order to screen and obtain circRNA that plays a key role in the process of myocardial fibrosis, so as to provide a drug for preparing myocardial fibrosis, the present invention provides a circSamd4, a vector for reducing the expression of circSamd4, a host cell containing the vector and its use in the preparation of a drug for treating myocardial fibrosis. The present invention discovered for the first time a circSamd4 that plays a key role in the process of myocardial fibrosis, the nucleotide sequence of which is shown in SEQ ID NO: 1 or SEQ ID NO: 2, and verified that knocking down circSamd4 expression can improve the impaired cardiac contractile function caused by thoracic aortic arch stenosis for 4 weeks, reduce myocardial fibrosis, and inhibit the activation of myocardial fibroblasts. It can be used to prepare a drug for treating myocardial fibrosis, and has important practical significance.

The application of a class of N-substituted phenyl-2-pyridone compounds in treating cancer and relieving fibrosis belongs to the technical field of medicine. The compound is an N-substituted phenyl-2-pyridone compound or a pharmaceutical derivative or preparation thereof. The cancer includes one or more of common cancers such as lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer and the like. The fibrosis disease includes one or more of diseases such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis and the like or diseases induced by fibrosis. The drug can be combined with one or more pharmaceutical carriers to form a drug combination. The drug or the pharmaceutical composition thereof can be used alone or in combination with other drugs. The class of N-substituted phenyl-2-pyridone compounds has anticancer efficacy and presents excellent ability to relieve organ and tissue fibrosis, has good safety, and is expected to be developed into a clinical first-line drug.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The present disclosure discloses use of a fused polypeptide with multifunctional activities. In the fused polypeptide with multifunctional activities, the polypeptide contains the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; or a sequence of any amino acid mutated in the foregoing domains. The fused polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, skin fibrosis, renal fibrosis, myocardial fibrosis, and lung tissue lesions.

The invention belongs to the technical field of cardiovascular disease research, and relates to snoRNA for detecting myocardial fibrosis as well as a detection method and application thereof. The invention discloses a specific snoRNA, which is named as CFASR, and the sequence of the specific snoRNA is shown as SEO ID NO. 1. Overexpression of the CFASR can remarkably inhibit myocardial fibrosis, and silence of the CFASR can promote fibrosis and effectively relieve the problem of cardiovascular diseases. As a therapeutic drug, the CFASR gene has a potential regulation effect in cardiovascular diseases, and provides a new target for prevention and treatment of cardiovascular diseases.

The present disclosure provides a pharmaceutical composition for regenerating myocardium, inhibiting myocardial fibrosis, or treating cardiac disease comprising a polynucleotide encoding a constitutive active IKK [beta].

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to clarify the effect of pan-connexin1 in the cardiac hypertrophy process caused by overload of pressure, the invention provides application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the invention, it is found for the first time that Pannexin1 is an effective target spot for treating myocardial hypertrophy caused by pressure overload, and an expression inhibitor for inhibiting Pannexin1 by targeting the target spot can be used for preparing drugs for treating myocardial hypertrophy caused by pressure overload. Therefore, the invention provides the application of the inhibitor targeting the Pannexin1 gene in preparation of the medicine for preventing or treating the myocardial fibrosis, and a new treatment mode is provided for treatment of the myocardial fibrosis.